US Employers to Cut GLP-1 Obesity Drug Coverage by 2027 Over Costs

Key Facts

In a move reflecting the growing challenges to healthcare cost sustainability, US employers are planning to scale back coverage for GLP-1 obesity medications by 2027. According to reports, a rising number of corporations and health plans intend to stop or limit coverage for drugs such as Ozempic, Wegovy, and Zepbound. This trend is driven by the surging costs of these medications, which are causing significant financial strain on corporate health benefit budgets.

These pressures emerge as pharmaceutical giants experience massive growth; Eli Lilly has reported robust Zepbound revenue in recent quarters, while Novo Nordisk continues to dominate with Wegovy. However, with treatment costs often exceeding $1,000 per month per patient, concerns are mounting. Per market data, investors are closely evaluating whether these manufacturers can sustain volume growth if insurance coverage narrows in their most critical global market.